
Upstart reported stellar Q2 results, with transaction volume surging 154% year-over-year and achieving positive net income for the first time in years, alongside a 21% adjusted EBITDA margin and a projected first-ever billion-dollar revenue year. Despite this strong performance, the stock declined post-earnings, reflecting investor caution. Key concerns include a 30% sequential increase in balance sheet loans, now exceeding $1 billion with 70% classified as 'R&D' loans, and a significant rise in loan conversion rates from 15.2% to 23.9%, which could suggest a potential relaxation of lending standards to maintain growth.
Upstart (UPST) delivered exceptionally strong second-quarter results, highlighted by a 154% year-over-year increase in transaction volume and revenue that more than doubled, defying a challenging high-interest-rate environment. The company achieved a significant milestone by reporting a positive net income for the first time in years, surpassing its own guidance which had projected a small loss, and posted a robust 21% adjusted EBITDA margin. Forward guidance remains optimistic, with a forecast for the company's first-ever billion-dollar revenue year and continued GAAP net income growth. However, the stock's decline post-earnings reflects significant investor caution centered on two key metrics. Firstly, the company is now carrying over $1 billion in loans on its balance sheet—a 30% sequential increase in R&D loans—creating a potential risk concentration. Secondly, the loan conversion rate surged from 15.2% to 23.9% year-over-year, which, coupled with a two-percentage-point sequential drop in loans to 'superprime' borrowers, raises concerns that lending standards may be relaxing to sustain high growth rates.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
-0.05
Ticker Sentiment